证券代码：688098 证券简称：申联生物 公告编号：2026-004 申联生物医药(上海)股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度及 减持计划完成暨减持股份结果公告 信息披露义务人UNITED BIOMEDICAL,INC.保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性和 完整性依法承担法律责任。本公司董事会及全体董事保证公告内容与信息披露义 务人提供的信息一致。 重要内容提示： 本次减持计划实施前，美国联合生物医药公司（UNITED BIOMEDICAL,I NC.以下简称"UBI"）持有申联生物医药（上海）股份有限公司（以下简称"公 司"或"申联生物"）43,199,898 股股份，占公司总股本的 10.52%。上述股份来源 为公司首次公开发行股票并上市前取得，且已于 2020 年 10 月 28 日后上市流通。 减持计划的实施结果情况 2025 年 10 月 23 日，公司在上海证券交易所网站（www.sse.com.cn）披 露《申联生物医药(上海)股份有限公司持股 5%以上股东减持股份计划公告》 （公告编号：2025-037）。 ...

格隆汇2月9日丨申联生物(688098.SH)公布，公司于2026年2月9日收到UBI出具的《UBI关于权益变动触 及1%刻度及减持计划完成暨减持股份结果的告知函》。截至本公告披露日，UBI已通过集中竞价及大 宗交易方式减持公司股份1231.92万股，占公司总股本的3.00%。本次减持计划已实施完毕。 ...

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

格隆汇1月30日丨申联生物(688098.SH)公布，公司于近日收到UNITED BIOMEDICAL,INC.（以下简 称"UBI"）出具的《UBI关于权益变动触及1%刻度的告知函》，UBI于2025年12月4日至2026年1月30日 期间减持公司股份710.404万股，占公司总股本的1.73%，其中通过集中竞价方式减持公司股份197.104 万股，通过大宗交易方式减持公司股份513.3万股。本次权益变动后，UBI持有公司股份比例由10.00% 降至8.27%，权益变动触及1%刻度。 ...

格隆汇1月30日丨申联生物(688098.SH)公布，公司于近日收到UNITED BIOMEDICAL,INC.（以下简 称"UBI"）出具的《UBI关于权益变动触及1%刻度的告知函》，UBI于2025年12月4日至2026年1月30日 期间减持公司股份710.404万股，占公司总股本的1.73%，其中通过集中竞价方式减持公司股份197.104 万股，通过大宗交易方式减持公司股份513.3万股。本次权益变动后，UBI持有公司股份比例由10.00% 降至8.27%，权益变动触及1%刻度。 ...

一、 信息披露义务人及其一致行动人的基本信息 证券代码：688098 证券简称：申联生物 公告编号：2026-003 申联生物医药（上海）股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 信息披露义务人 UNITED BIOMEDICAL, INC.保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏，并对其真 实性、准确性和完整性依法承担法律责任。本公司董事会及全体董事保证 公告内容与信息披露义务人提供的信息一致。 公司于近日收到 UNITED BIOMEDICAL,INC（. 以下简称"UBI"）出具的《UBI 关于权益变动触及 1%刻度的告知函》，UBI 于 2025 年 12 月 4 日至 2026 年 1 月 30 日期间减持公司股份 710.404 万股，占公司总股本的 1.73%，其中通过集中 竞价方式减持公司股份 197.104 万股，通过大宗交易方式减持公司股份 513.3 万 股。本次权益变动后，UBI 持有公司股份比例由 10.00%降至 8.27%，权益变动 触及 1%刻度。具体情况如下： | 投资者名称 | 变动前股数 | 变动前比例 ...

1月30日，申联生物大宗交易成交308万股，成交额2710.4万元，占当日总成交额的35.9%，成交价8.8 元，较市场收盘价9.53元折价7.66%。 | of the support of the vice | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | 026-01-30 | 中联生物 | 688098 | 2710.4 8.8 | 308 | 有廣迭論严落劈毀 | 蛋白菜餐廳服裝酵 | | 190 | ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]